June Business and People Slideshow
Business and people highlights from our June issue, including four recent hires and a new facility in the UK.
James Dixon
Bringing with him more than 25 years in the pharmaceutical, biotechnology, and CRO industries, James Dixon has been named Senior Vice President, Quality and Compliance at Cetero Research (Cary, NC).
Richard Farris
Novella Clinical (Research Triangle Park, NC) has made several changes to its team including the appointment of Richard Farris as Senior Director for Project Management and the promotion of Michael Doyle to Global Head of Regulatory Affairs.
Robin Sutherland
Quanticate (Cambridge, MA) has appointed Robin Sutherland as Head of US Operations where she will be responsible for all aspects of business expansion across the United States and Canada.
Dawn Duggan
Dawn Duggan has joined A10 Clinical Solutions (Cary, NC) as Director of Strategic Clinical Solutions where she will be responsible for strategically growing A10’s presence within the northeastern US pharmaceutical and biotechnology hub.
Dr. Reddy’s Laboratories
Pictured above: Y. Hamied, PhD, Chairman of Cipla and Honorary Fellow of Christ’s College, Cambridge, and G. V. Prasad, Vice Chairman and CEO.
Dr. Reddy’s Laboratories has opened a newly expanded Chirotech Technology Center at Cambridge Science Park, UK where Chirotech has been based for the last 20 years. The new 33,000 sq ft facility is purpose built for laboratories and offices and has been fitted to Dr. Reddy’s specific requirements for chemistry, biology and analytics.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
